## bsm-0387M

## [ Primary Antibody ]

www.bioss.com.cn sales@bioss.com.cn techsupport@bioss.com.cn 400-901-9800

# TNF alpha(1F6) Mouse mAb

DATASHEET -

Host: Mouse Isotype: IgG Clonality: Monoclonal CloneNo.: 1F6 **GeneID:** 7124 **SWISS:** P01375

Target: TNF alpha(1F6)

Immunogen: Recombinant human TNF alpha protein: 77-233/233.

Purification: affinity purified by Protein G

Concentration: 1mg/ml

Storage: Size: 50ul/100ul/200ul

0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50%

Glycerol.

Size: 200ug (PBS only)

0.01M PBS

Shipped at 4°C. Store at -20°C for one year. Avoid repeated

freeze/thaw cycles.

**Background:** This gene encodes a multifunctional proinflammatory cytokine that belongs to the tumor necrosis factor (TNF) superfamily. This cytokine is mainly secreted by macrophages. It can bind to, and thus functions through its receptors TNFRSF1A/TNFR1 and TNFRSF1B/TNFBR. This cytokine is involved in the regulation of a wide spectrum of biological processes including cell proliferation, differentiation, apoptosis, lipid metabolism, and coagulation. This cytokine has been implicated in a variety of diseases, including autoimmune diseases, insulin resistance, psoriasis, rheumatoid arthritis ankylosing spondylitis, tuberculosis, autosomal dominant polycystic kidney disease, and cancer. Mutations in this gene affect susceptibility to cerebral malaria, septic shock, and Alzheimer disease. Knockout studies in mice also suggested the neuroprotective function of this cytokine. [provided by RefSeq, Aug 2020]


**Applications: Flow-Cyt** (1ug/Test) ICC/IF (1:100-500)

Reactivity: Human


Predicted MW.: 17/26 kDa

Subcellular Secreted ,Cell membrane

### VALIDATION IMAGES



(LPS (100 ng/ml, 16 h) and Brefeldin A treated (5 μg/ml, 4 h)) THP-1 (H) cells; Antibody incubation with (TNF alpha) monoclonal Antibody, unconjugated (bsm-0387M) 1:100, 90 min at 37°C; followed by conjugated Goat Anti-Mouse IgG antibody (green, bs-60296G-BF488) at 37°C for 90 min, DAPI (blue, C02-04002) was used to stain the cell nuclei. PBS instead of the primary antibody was used as the blank control.



Blank control:THP-1. Primary Antibody (green line): Mouse Anti-TNF alpha antibody (bsm-0387M) Dilution: 1ug/Test; Secondary Antibody: Goat anti-mouse IgG-BF488 Dilution: 0.5ug/Test. The cells were treated with TPA (80 nM, overnight) and then treated with LPS (1 ug/mL, 18 hr/6 hr) and Brefeldin A (300 ng/mL, last 3 hr of stimulation) .The cells were fixed with 4% PFA (10min at room temperature) and then permeabilized with 90% ice-cold methanol for 20 min at -20°C. The cells were then incubated in 5%BSA to block non-specific protein-protein interactions for 30 min at room temperature .Cells stained with Primary Antibody for 30 min at room temperature. The secondary antibody used for 40 min at room temperature. Acquisition of 20,000 events was performed.

#### - SELECTED CITATIONS -

- [IF=20.722] Meng Lin. et al. CRISPR-based in situ engineering tumor cells to reprogram macrophages for effective cancer immunotherapy. Nano Today. 2022 Feb;42:101359 IF; Mouse. 10.1016/j.nantod.2021.101359
- [IF=14.593] Ya-nan Fu. et al. Spatiotemporally dynamic therapy with shape-adaptive drug-gel for the improvement of tissue regeneration with ordered structure. Bioact Mater. 2021 Jun;: IHC; Rat. 10.1016/j.bioactmat.2021.06.015
- [IF=3.532] Quan Zhang. et al. Intra-articular injection of human umbilical cord mesenchymal stem cells ameliorates monosodium iodoacetate-induced osteoarthritis in rats by inhibiting cartilage degradation and inflammation. Bone Joint Res. 2021 Mar; 10(3): 226–236 IHC; Rat. 33739851
- [IF=3.17] Zhang, Jia xiang, et al. "Complement C5a-C5aR interaction enhances MAPK signaling pathway activities to mediate renal injury in trichloroethylene sensitized BALB/c mice." Journal of Applied Toxicology (2015). IHC ;="Mouse". 26095957
- [IF=1.813] Zhao Hong. et al. Study on Network Pharmacological Analysis and Preliminary Validation to Understand the Mechanisms of Plantaginis Semen in Treatment of Gouty Nephropathy. Evid-Based Compl Alt. 2020;2020:8861110 IHC ;Rat. 33312224